Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
September 02 2020 - 8:00PM
Telix Pharmaceuticals Enters Strategic Collaboration with Varian
Medical Systems for Advanced Prostate Imaging
Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’)
today announced it has entered into a strategic collaboration
agreement with Palo Alto-based Varian Medical Systems, to evaluate
the use of advanced prostate cancer imaging within Varian’s
radiation treatment planning platform.
Under the terms of the agreement, the parties
will leverage Telix’s extensive clinical data for imaging
prostate-specific membrane antigen (PSMA) with positron emission
tomography (PET) to potentially develop new image-guided treatment
planning functions, automated analysis and artificial intelligence
capabilities within Varian’s radiation treatment planning
technology platforms. The goal of the collaboration is to ensure
that the latest standard of care in prostate imaging is able to be
an integral part of radiation treatment planning.
Telix CEO Dr Christian Behrenbruch said
“Advanced prostate imaging techniques using PET/CT have evolved as
a new standard of care for imaging patients across the prostate
cancer continuum, from early through to the advanced stages of
disease.1 Given that radiation therapy is a mainstay of treatment
for patients with prostate cancer, we believe it is vitally
important that we work with Varian, the radiation oncology market
leader, to ensure all men with prostate cancer are offered
radiation therapy for maximum clinical benefit.”
Dr Corey Zankowski, Senior Vice President of
Varian’s Oncology Software Solutions said “The additional
diagnostic and cancer staging information provided by PSMA PET/CT
imaging may offer important insights that impact clinical care
decisions for prostate cancer patients. This collaboration with
Telix will investigate the potential to incorporate this rich
diagnostic information into Varian’s bioinformatics and radiation
treatment planning platforms to generate highly personalized and
targeted radiation therapy for men with prostate cancer.”
About Prostate Cancer
Prostate cancer is the most common cancer in
men, with an estimated 192,000 new cases and 33,000 deaths from
prostate cancer in the United States expected in 2020.2 Prostate
cancer is more common in older men, with approximately 60% of cases
diagnosed in men over 65 years of age. Due to high rates of
screening, over 90% of prostate cancers are diagnosed early, when
the disease is localised to the prostate or nearby tissues. Both
surgery and radiation therapy are effective treatment options for
men with localised prostate cancer, offering 5-year survival rates
over 95%. More than 60,000 men in the United States undergo
radiation therapy for prostate cancer annually,3 with advances in
medical imaging and radiation treatment planning continuing to
increase the effectiveness and reduce the side effects of radiation
therapy.4
_____________1 Trabulsi EJ, et al. Optimum
Imaging Strategies for Advanced Prostate Cancer; ASCO Guideline. J
Clin Oncol 38: 1963 – 1996 (published online January 15, 2020).2
American Cancer Society:
https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html.3
Prostate Cancer Foundation:
https://www.pcf.org/c/treatment-for-prostate-cancer-external-beam-radiation-therapy/.4
Garibaldi c, et al. Recent advances in radiation oncology.
Ecancermedicalscience. 2017; 11: 85.
About Telix Pharmaceuticals
Limited
Telix is a clinical-stage biopharmaceutical
company focused on the development of diagnostic and therapeutic
products using Molecularly Targeted Radiation (MTR). Telix is
headquartered in Melbourne with international operations in
Belgium, Japan and the United States. Telix is developing a
portfolio of clinical-stage oncology products that address
significant unmet medical needs in prostate, kidney and brain
cancer. Telix is listed on the Australian Securities Exchange (ASX:
TLX). For more information visit www.telixpharma.com.
About Varian Medical Systems
Inc.
At Varian, we envision a world without fear of
cancer. For more than 70 years, we have developed, built and
delivered innovative cancer care technologies and solutions for our
clinical partners around the globe to help them treat millions of
patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 countries
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
Telix Corporate ContactDr Christian
BehrenbruchTelix Pharmaceuticals LimitedCEOEmail:
chris@telixpharma.com |
Telix Investor RelationsDr David N. CadeTelix
Pharmaceuticals LimitedCBO and Head of Investor RelationsEmail:
david.cade@telixpharma.com |
Telix Pharmaceuticals (ASX:TLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Telix Pharmaceuticals (ASX:TLX)
Historical Stock Chart
From Apr 2023 to Apr 2024